This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
- Investigator
- Tung T Wynn
- Status
- Accepting Candidates
- Ages
- 12 Years - 75 Years
- Sexes
- All
Pediatric Hematologist/Oncologist (Child Cancer Specialist)
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von…
28 publications
2026
Special Care in Dentistry
Publisher's site2025
JAMA
PubMed • Publisher's site2025
EJIFCC
PubMed2025
JMIR XR and Spatial Computing
Publisher's site2025
Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
PubMed • Publisher's site